ReviewBiomedicines2023
Oral Cavity Squamous Cell Carcinoma: An Update of the Pharmacological Treatment.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- The effectiveness of gender-neutral HPV vaccination programmes in preventing HPV-associated oral cancers: a systematic review.BMC cancer · 2026Pooled it
- Compartment-specific oxidative stress signatures in oral leukoplakia: a systematic review of local and systemic biomarkers.Frontiers in physiology · 2026Pooled it
- From signals to phenotype: multifactorial drivers of tumor-associated macrophage polarization in oral cavity squamous cell carcinoma: a narrative review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Review
- Article
- Integrating RNA-seq and Single-Cell RNA-seq to Uncover Transcriptional Signature of Fibroblasts in Oral Squamous Cell Carcinoma.Biochemical genetics · 2026Article
- Trends and Patterns in Oral and Maxillofacial Biopsies in a Tertiary Care Centre of Jharkhand.Cureus · 2026Article
- The oral microbiota in oral squamous cell carcinoma: unravelling mechanisms and clinical potential.Cancer cell international · 2026Review
- Performance of Machine Learning Models for Prognosis Prediction in Oral Cavity Squamous Cell Carcinoma: A Systematic Review.Cancers · 2026Review
- Article
- FoxP3+ Cells and PNAd+ Tumour-Associated High Endothelial Venules: Synergistic Prognostic Markers in Oral Tongue Squamous Cell Carcinoma.Head and neck pathology · 2026Article
- Diagnostic Accuracy and Clinical Utility of Salivary Biomarkers in Oral Squamous Cell Carcinoma: A Meta-Analysis.Cancers · 2026Review
- Iron homeostasis and macrophage polarization in oral squamous cell carcinoma: mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
- MicroRNA-mediated MAPK signaling promotes isoliensinine-induced apoptosis in oral squamous cell carcinoma via the ROS-dependent mitochondrial pathway and G2 phase arrest.American journal of cancer research · 2026Article
- Attention-aided hybrid transformer network for oral squamous cell carcinoma classification using histopathology images.Frontiers in artificial intelligence · 2026Article
- PI3K/mTOR inhibition attenuates cigarette smoke-induced senescence and SASP in oral fibroblasts: implications for tumor microenvironment remodeling.Frontiers in cell and developmental biology · 2026Article
- Complications Following Karapandzic Flap Reconstruction of the Lip: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Article
- Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation.BMC pharmacology & toxicology · 2025Article
- Research on the expression, prognostic value, and regulatory effects on immune microenvironment of NETO2 in oral squamous cell carcinoma.BMC cancer · 2025Article
- Review
- PIAS1 Shapes a Tumor-Suppressive Microenvironment by Suppressing Immune Evasion in Oral Squamous Cell Carcinoma.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral cavity squamous cell carcinoma (OCSCC) represents a serious health and socio-economic problem in different geographical areas of the world. It is characterized by a high rate of mortality, recurrence and metastasis. Despite the therapeutic strategies implemented for its management and resolution, currently the survival estimate for locally advanced disease is about 50%. The available therapeutic options comprise surgery and pharmacological treatment. Recently, an increased emphasis has been placed on the drugs that might be of benefit in this life-threatening disease. Therefore, the aim of this present review was to offer a general survey of the current available pharmacological treatment for OCSCC. The PubMed database was used to retrieve the papers using "OCSCC" as the search terms. We limited our search to the last 5 years to give a more updated and recent picture of the state of the art, including preclinical and clinical investigations. We found that 77 out of 201 papers were on the surgical treatment of OCSCC, 43 out of 201 focused on the radiotherapy and 81 out of 201 underwent evaluation for the aim of our review. We excluded the case reports, editorial letters, observational studies and papers written in languages other than English. A total of 12 articles were included in the final review. Our results showed that nanotechnologies use to enhance the efficacy of anticancer drugs such as: cisplatin, paclitaxel, cetuximab, EGFR antagonists, MEK1/2 and immune check inhibitors combination could have promising anti-cancer activity. However, the paucity of available data on drugs suggests the urgent need to improve the pharmacological armamentarium for OCSCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.